Therapeutic drug monitoring - identification of adverse reactions

Role

Therapeutic drug monitoring helps identify emerging adverse drug reactions before they become clinically severe - a rising level approaching or exceeding the toxic range, even without yet-obvious clinical toxicity symptoms, should prompt dose reduction or closer monitoring rather than waiting for symptoms to develop
Relevant to every drug with established therapeutic drug monitoring, given the direct relationship between supratherapeutic levels and adverse effect risk for these narrow therapeutic index agents

For narrow therapeutic index drugs, the margin between therapeutic and toxic plasma concentration is small, meaning relatively modest changes in clearance (from renal/hepatic impairment, drug interactions, or dose changes) can push levels from therapeutic into the toxic range - proactive level monitoring identifies this drift before clinical toxicity manifests, particularly valuable since early toxicity symptoms can be subtle or non-specific

Levels should be interpreted alongside clinical assessment for emerging toxicity symptoms specific to the monitored drug (e.g. lithium - tremor, confusion, GI symptoms; digoxin - visual disturbance, arrhythmia; anticonvulsants - ataxia, sedation)
A level within the therapeutic range does not fully exclude toxicity in an individual patient with unusual sensitivity, and clinical correlation always remains necessary alongside the numerical result

Dose reduction or temporary cessation for a level approaching/exceeding the toxic range, even in the absence of overt clinical toxicity symptoms, as a proactive rather than reactive safety measure
Identifying and addressing the underlying cause of a rising level (new interacting drug, declining renal/hepatic function, dose change) rather than simply treating the abnormal level in isolation

Lithium toxicity progression (mild tremor to severe neurotoxicity as levels rise), digoxin toxicity and its characteristic visual/GI/arrhythmic features, anticonvulsant level-toxicity relationship, proactive vs reactive monitoring philosophy

Therapeutic drug monitoring should be used proactively to catch a rising level before clinical toxicity develops, not simply to confirm toxicity once symptoms have already appeared - this is the core value proposition of monitoring narrow therapeutic index drugs, allowing dose adjustment before the patient experiences preventable harm

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.